{
    "clinical_study": {
        "@rank": "92459", 
        "brief_summary": {
            "textblock": "Cigarette smoking is the major cause of chronic obstructive pulmonary disease (COPD), the\n      4th cause of mortality in the US. Central to COPD pathogenesis is \"ciliopathy\", dysfunction\n      of the airway ciliated cells that mediate transport of mucus to remove inhaled pathogens.\n      The focus of this study is to carry out metabolic profiling of banked biologic samples and\n      assess the hypothesis that COPD is associated with a unique metabolome in serum and lung\n      epithelial lining fluid, and that subsets of the COPD metabolome are linked to the\n      ciliopathy of COPD."
        }, 
        "brief_title": "COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function", 
        "condition": [
            "COPD", 
            "Smoking", 
            "Non-smoker"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pulmonary Disease, Chronic Obstructive", 
                "Smoking"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All study subjects should be able to provide informed consent Males or females ages 18\n        years and older Must provide HIV informed consent Lung disease proven by at least one of\n        the following: symptoms     consistent with pulmonary disease; (2) chest X-rays consistent\n        with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung\n        biopsy consistent with lung disease; (5) family history of lung disease; and/or (6)\n        diseases of organs with known association with lung disease\n\n        Exclusion Criteria:\n\n        Individuals not deemed in good overall health by the investigator will not be accepted\n        into the study.\n\n        Habitual use of drugs and/or alcohol within the past six months (Acceptable: Marijuana one\n        time in three months; average of two alcoholic beverages per day; drug and/or alcohol\n        abuse is defined as per the DSM-IV Substance Abuse Criteria).\n\n        Individuals with history of chronic lung disease, including asthma or with recurrent or\n        recent (within three months) acute pulmonary disease will not be accepted into the study.\n\n        Individuals with allergies to atropine or any local anesthetic will not be accepted into\n        the study.\n\n        Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or\n        aminophylline will not be accepted into the study.\n\n        Females who are pregnant or nursing will not be accepted into the study Any history of\n        allergies to xylocaine, lidocaine, versed, valium, atropine, pilocarpine, isoproterenol,\n        terbutaline, aminophylline, or any local anesthetic will not be included in the study\n        Patient refuses consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "New York Metropolitan area residents"
            }
        }, 
        "enrollment": {
            "#text": "226", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974154", 
            "org_study_id": "1305013966", 
            "secondary_id": "RFA-HL-12-009"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Smoking", 
            "Non-smoker"
        ], 
        "lastchanged_date": "October 25, 2013", 
        "number_of_groups": "1", 
        "official_title": "COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will perform metabolic profiling of biologic samples to assess the hypothesis that smoking-induced COPD is associated with a unique metabolome in serum and lung ELF, and that subsets of the COPD metabolome are linked to the ciliopathy of COPD.", 
            "measure": "Gene expression changes in airway epithelium", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974154"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Weill Medical College of Cornell University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Weill Medical College of Cornell University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}